 Englewood Cliffs, NJ, May 13, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTCQB: SILO a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its investigator led study using Psilocybin to treat Parkinsons disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders. 